SEARCH

SEARCH BY CITATION

References

  • Bates G., Harper P. and Jones L. (2002) Huntington's Disease, 3rd edn. pp. 159197. Oxford University Press, Oxford.
  • Bence N. F., Sampat R. M. and Kopito R. R. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 15521555.
  • Caricchio R., Kovalenko D., Kaufmann W. K. and Cohen P. L. (1999) Apoptosis provoked by the oxidative stress inducer menadione (Vitamin K(3) is mediated by the Fas/Fas ligand system. Clin. Immunol. 93, 6574.
  • Chang D. T., Rintoul G. L., Pandipati S. and Reynolds I. J. (2006) Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol. Dis. 22, 388400.
  • Chapple S. J., Siow R. C. and Mann G. E. (2012) Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging. Int. J. Biochem. Cell Biol. 44, 13151320.
  • Clarke J. D., Hsu A., Williams D. E., Dashwood R. H., Stevens J. F., Yamamoto M. and Ho E. (2011) Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice. Pharm. Res. 28, 31713179.
  • Dong G., Ferguson J. M., Duling A. J. et al. (2011) Modeling pathogenesis of Huntington's disease with inducible neuroprogenitor cells. Cell. Mol. Neurobiol. 31, 737747.
  • Dong G., Callegari E., Gloeckner C. J., Ueffing M. and Wang H. (2012a) Mass spectrometric identification of novel posttranslational modification sites in Huntingtin. Proteomics 12, 20602064.
  • Dong G., Callegari E. A., Gloeckner C. J., Ueffing M. and Wang H. (2012b) Prothymosin-alpha interacts with mutant huntingtin and suppresses its cytotoxicity in cell culture. J. Biol. Chem. 287, 12791289.
  • Dong G., Gross K., Qiao F. et al. (2012c) Calretinin interacts with huntingtin and reduces mutant huntingtin-caused cytotoxicity. J. Neurochem. 123, 437446.
  • Fahey J. W. and Talalay P. (1999) Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food and Chem. Toxicol. 37, 973979.
  • Gamet-Payrastre L., Li P. F., Lumeau S., Cassar G., Dupont M. A., Chevolleau S., Gasc N., Tulliez J. and Terce F. (2000) Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 60, 14261433.
  • Gan N., Wu Y. C., Brunet M., Garrido C., Chung F. L., Dai C. and Mi L. (2010) Sulforaphane activates heat shock response and enhances proteasome activity through up-regulation of Hsp27. J. Biol. Chem. 285, 3552835536.
  • Goswami A., Dikshit P., Mishra A., Mulherkar S., Nukina N. and Jana N. R. (2006) Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem. Biophys. Res. Commun. 342, 184190.
  • Hanlon N., Coldham N., Gielbert A., Kuhnert N., Sauer M. J., King L. J. and Ioannides C. (2008) Absolute bioavailability and dose-dependent pharmacokinetic behaviour of dietary doses of the chemopreventive isothiocyanate sulforaphane in rat. Br. J. Nutr. 99, 559564.
  • Herman-Antosiewicz A., Johnson D. E. and Singh S. V. (2006) Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells. Cancer Res. 66, 58285835.
  • Jin Y. N., Yu Y. V., Gundemir S., Jo C., Cui M., Tieu K. and Johnson G. V. (2013) Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. PLoS ONE 8, e57932.
  • Kabeya Y., Mizushima N., Ueno T., Yamamoto A., Kirisako T., Noda T., Kominami E., Ohsumi Y. and Yoshimori T. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 19, 57205728.
  • Kensler T. W., Wakabayashi N. and Biswal S. (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89116.
  • Keum Y. S., Khor T. O., Lin W., Shen G., Kwon K. H., Barve A., Li W. and Kong A. N. (2009) Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway. Pharm. Res. 26, 23242331.
  • Kim H. V., Kim H. Y., Ehrlich H. Y., Choi S. Y., Kim D. J. and Kim Y. (2013) Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model. Amyloid, 20, 712.
  • Kisselev A. F. and Goldberg A. L. (2005) Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol. 398, 364378.
  • Kumarapeli A. R., Horak K. M., Glasford J. W., Li J., Chen Q., Liu J., Zheng H. and Wang X. (2005) A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. FASEB J. 19, 20512053.
  • Kwak M. K., Cho J. M., Huang B., Shin S. and Kensler T. W. (2007) Role of increased expression of the proteasome in the protective effects of sulforaphane against hydrogen peroxide-mediated cytotoxicity in murine neuroblastoma cells. Free Radical Biol. Med. 43, 809817.
  • Li X. J. and Li S. (2011) Proteasomal dysfunction in aging and Huntington disease. Neurobiol. Dis. 43, 48.
  • Li X., Li H. and Li X. J. (2008) Intracellular degradation of misfolded proteins in polyglutamine neurodegenerative diseases. Brain Res. Rev. 59, 245252.
  • Li J., Powell S. R. and Wang X. (2011) Enhancement of proteasome function by PA28α overexpression protects against oxidative stress. FASEB J. 25, 883893.
  • Liang Q., Ouyang X., Schneider L. and Zhang J. (2011) Reduction of mutant huntingtin accumulation and toxicity by lysosomal cathepsins D and B in neurons. Mol Neurodegener. 6, 37.
  • Liu J., Zheng H., Tang M., Ryu Y. C. and Wang X. (2008) A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. Am. J. Physiol. Heart Circ. Physiol. 295, H2541H2550.
  • Mizushima N. and Yoshimori T. (2007) How to interpret LC3 immunoblotting. Autophagy 3, 542545.
  • Morroni F., Tarozzi A., Sita G., Bolondi C., Zolezzi Moraga J. M., Cantelli-Forti G. and Hrelia P. (2013) Neuroprotective effect of sulforaphane in 6-hydroxydopamine-lesioned mouse model of Parkinson's disease. Neurotoxicology 36C, 6371.
  • Ogata M., Hino S., Saito A. et al. (2006) Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol. Cell. Biol. 26, 92209231.
  • Ravikumar B., Vacher C., Berger Z. et al. (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36, 585595.
  • Rubinsztein D. C. (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443, 780786.
  • Seo H., Sonntag K. C. and Isacson O. (2004) Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol. 56, 319328.
  • Seo H., Sonntag K. C., Kim W., Cattaneo E. and Isacson O. (2007) Proteasome activator enhances survival of huntington's disease neuronal model cells. PLoS ONE 2, e238.
  • Vyas A. R., Hahm E. R., Arlotti J. A., Watkins S., Stolz D. B., Desai D., Amin S. and Singh S. V. (2013) Chemoprevention of prostate cancer by d, l-sulforaphane is augmented by pharmacological inhibition of autophagy. Cancer Res. 73, 59855995.
  • Wang H., Lim P. J., Yin C., Rieckher M., Vogel B. E. and Monteiro M. J. (2006) Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin. Hum. Mol. Genet. 15, 10251041.
  • Wojcik C. and DeMartino G. N. (2003) Intracellular localization of proteasomes. Int. J. Biochem. Cell Biol. 35, 579589.
  • Zhang Y., Talalay P., Cho C. G. and Posner G. H. (1992) A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl Acad. Sci. USA 89, 23992403.
  • Zoghbi H. Y. and Orr H. T. (2000) Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217247.